- Understand $meso stock

$MESO Market Cap: $1.078 Billion

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$9.600M

TTM

Gross Margin

-224.79%

TTM

Net Earnings

-$97.54M

TTM

Current Assets

$85.15M

Q4 2023

Current Liabilities

$31.37M

Q4 2023

Current Ratio

271.48%

Q4 2023

Total Assets

$670.3M

Q4 2023

Total Liabilities

$161.6M

Q4 2023

Book Value

$508.7M

Q4 2023

Cash

P/E

-11.05

Sep 18, 2024 EST

Free Cash Flow

-$75.87M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005
Revenue	$7.501M	$10.21M	$7.456M	$32.16M	$16.72M	$17.34M	$2.412M	$42.55M	$19.76M	$23.84M	$29.52M	$39.34M	$18.99M	$660.0K	$650.0K	$810.0K	$1.320M	$2.110M	$380.0K
YoY Change	-26.56%	36.99%	-76.81%	92.3%	-3.57%	618.95%	-94.33%	115.31%	-17.11%	-19.24%	-24.96%	107.16%	2777.27%	1.54%	-19.75%	-38.64%	-37.44%	455.26%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005
Revenue	$7.501M	$10.21M	$7.456M	$32.16M	$16.72M	$17.34M	$2.412M	$42.55M	$19.76M	$23.84M	$29.52M	$39.34M	$18.99M	$660.0K	$650.0K	$810.0K	$1.320M	$2.110M	$380.0K
Cost Of Revenue	$27.73M	$30.76M	$32.72M	$25.31M	$15.36M	$5.508M	$12.07M	$29.76M	$23.78M	$25.33M	$21.48M	$22.70M
Gross Profit	-$20.23M	-$20.54M	-$25.26M	$6.847M	$1.364M	$11.83M	-$9.653M	$12.79M	-$4.022M	-$1.490M	$8.040M	$16.64M
Gross Profit Margin	-269.72%	-201.13%	-338.83%	21.29%	8.16%	68.24%	-400.21%	30.05%	-20.35%	-6.25%	27.24%	42.3%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005
Selling, General & Admin	$25.37M	$27.21M	$30.87M	$25.61M	$21.63M	$21.91M	$23.01M	$22.50M	$29.54M	$23.50M	$31.51M	$28.92M	$11.68M	$3.140M	$2.330M	$2.360M	$3.220M	$2.800M	$500.0K
YoY Change	-6.75%	-11.85%	20.53%	18.42%	-1.29%	-4.78%	2.25%	-23.83%	25.7%	-25.42%	8.96%	147.6%	271.97%	34.76%	-1.27%	-26.71%	15.0%	460.0%
% of Gross Profit				374.02%	1585.41%	185.13%		175.99%			391.92%	173.8%
Research & Development	$27.19M	$32.82M	$51.54M	$54.73M	$58.36M	$64.31M	$58.91M	$50.01M	$62.65M	$50.74M	$44.20M	$38.09M	$15.10M	$6.660M	$5.250M	$5.550M	$3.600M	$4.000M	$570.0K
YoY Change	-17.14%	-36.33%	-5.84%	-6.21%	-9.25%	9.16%	17.8%	-20.17%	23.47%	14.8%	16.04%	152.25%	126.73%	26.86%	-5.41%	54.17%	-10.0%	601.75%
% of Gross Profit				799.37%	4278.59%	543.49%		391.18%			549.75%	228.91%
Depreciation & Amortization	$1.462M	$1.462M	$1.475M	$1.455M	$1.455M	$1.616M													$80.00K
YoY Change	0.0%	-0.88%	1.37%	0.0%	-9.96%
% of Gross Profit				21.25%	106.67%	13.66%
Operating Expenses	$27.19M	$32.82M	$65.12M	$80.34M	$87.83M	$76.14M	$80.52M	$31.25M	$87.77M	$66.35M	$69.64M	$66.88M	$26.79M	$9.800M	$7.580M	$7.920M	$6.820M	$6.810M	$1.160M
YoY Change	-17.14%	-49.61%	-18.94%	-8.53%	15.35%	-5.44%	157.66%	-64.4%	32.28%	-4.72%	4.13%	149.65%	173.37%	29.29%	-4.29%	16.13%	0.15%	487.07%
Operating Profit	-$47.42M	-$53.36M	-$90.39M	-$73.49M	-$86.47M	-$64.31M	-$90.17M	-$18.47M	-$91.79M	-$67.84M	-$61.60M	-$50.24M
YoY Change	-11.13%	-40.97%	22.99%	-15.0%	34.45%	-28.68%	388.34%	-79.88%	35.31%	10.13%	22.61%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005
Interest Expense	$19.44M	$16.91M	-$14.47M	-$14.47M	-$11.91M	-$1.668M	-$43.00K	-$1.126M	$10.48M	-$3.650M		$0.00	-$1.450M	-$3.870M	-$2.100M	-$1.900M	-$1.350M	-$1.500M	-$360.0K
YoY Change	15.01%	-216.85%	-0.01%	21.47%	614.15%	3779.07%	-96.18%	-110.75%	-387.07%			-100.0%	-62.53%	84.29%	10.53%	40.74%	-10.0%	316.67%
% of Operating Profit
Other Income/Expense, Net							$0.00	-$9.311M	-$8.099M	-$1.660M	$0.00	-$130.0K
YoY Change							-100.0%	14.96%	387.89%		-100.0%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005
Pretax Income	-$82.10M	-$91.59M	-$99.63M	-$87.36M	-$98.75M	-$65.98M	-$90.22M	-$90.82M	-$96.24M	-$74.27M	-$61.60M	-$50.24M	$90.98M	-$13.01M	-$9.030M	-$9.000M	-$6.850M	-$6.200M	-$1.140M
YoY Change	-10.36%	-8.07%	14.05%	-11.54%	49.68%	-26.87%	-0.67%	-5.63%	29.59%	20.57%	22.61%	-155.22%	-799.31%	44.08%	0.33%	31.39%	10.48%	443.86%
Income Tax	-$212.0K	-$239.0K	-$819.0K	-$9.415M	-$8.955M	-$30.69M	-$13.40M	-$86.69M	$0.00	$0.00	$1.630M	$23.12M	$1.610M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
% Of Pretax Income													1.77%
Net Earnings	-$81.89M	-$91.35M	-$98.81M	-$77.94M	-$89.80M	-$35.29M	-$76.82M	-$4.127M	-$96.24M	-$74.28M	-$63.23M	-$73.36M	$89.36M	-$13.01M	-$9.030M	-$9.000M	-$6.850M	-$6.200M	-$1.140M
YoY Change	-10.35%	-7.55%	26.78%	-13.21%	154.46%	-54.06%	1761.28%	-95.71%	29.57%	17.48%	-13.81%	-182.09%	-786.86%	44.08%	0.33%	31.39%	10.48%	443.86%
Net Earnings / Revenue	-1091.71%	-894.33%	-1325.25%	-242.38%	-537.01%	-203.51%	-3184.7%	-9.7%	-487.04%	-311.58%	-214.19%	-186.48%	470.56%	-1971.21%	-1389.23%	-1111.11%	-518.94%	-293.84%	-300.0%
Basic Earnings Per Share
Diluted Earnings Per Share	-$0.11	-$140.8K	-$163.3K	-$147.4K	-$181.6K	-$75.78K	-$192.4K	-$11.32K	-$296.9K	-$230.2K	-$213.8K	-$256.8K	$388.4K	-$91.63K	-$71.97K	-$78.02K	-$63.71K	-$65.64K	-$15.78K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005
Cash & Short-Term Investments	$70.92M	$60.05M	$136.4M	$128.9M	$50.03M	$37.61M	$45.51M	$80.93M	$110.7M	$185.2M	$288.1M	$211.6M	$282.1M	$27.70M	$13.30M	$13.50M	$10.20M	$5.800M	$11.50M
YoY Change	18.1%	-55.97%	5.78%	157.72%	33.0%	-17.35%	-43.77%	-26.89%	-40.23%	-35.72%	36.15%	-24.99%	918.41%	108.27%	-1.48%	32.35%	75.86%	-49.57%
Cash & Equivalents	-$2.000K	$13.00K	-$49.00K	$12.00K	$21.00K	$142.0K	$37.54M	$59.07M	$89.58M	$181.6M	$280.9M	$900.0K	$600.0K	$5.500M	$800.0K	$4.100M	$10.20M	$5.800M	$11.50M
Short-Term Investments						$250.0K	$250.0K					$208.1M	$278.1M	$22.10M	$12.30M	$8.700M
Other Short-Term Assets	$3.742M	$5.387M	$7.004M	$6.046M	$8.436M	$13.34M	$14.61M	$3.837M	$7.787M	$1.200M	$4.100M	$300.0K	$200.0K	$100.0K	$100.0K	$100.0K	$0.00	$100.0K	$0.00
YoY Change	-30.54%	-23.09%	15.85%	-28.33%	-36.77%	-8.65%	280.68%	-50.73%	548.92%	-70.73%	1266.67%	50.0%	100.0%	0.0%	0.0%		-100.0%
Inventory
Prepaid Expenses
Receivables	$2.276M	$2.224M	$2.000M	$678.0K	$1.741M	$6.711M	$594.0K	$702.0K	$136.0K	$0.00	$0.00	$2.200M	$100.0K	$100.0K	$100.0K	$0.00	$300.0K
Other Receivables	$4.722M	$2.179M	$2.842M	$896.0K	$2.319M	$43.41M	$2.899M	$3.352M	$3.836M	$5.800M	$11.00M	$8.700M	$2.200M	$300.0K	$100.0K	$100.0K	$100.0K
Total Short-Term Assets	$81.66M	$69.84M	$148.2M	$136.5M	$62.52M	$101.1M	$63.61M	$88.82M	$122.5M	$192.1M	$303.2M	$222.8M	$284.5M	$28.20M	$13.60M	$13.70M	$10.70M	$6.000M	$11.70M
YoY Change	16.93%	-52.89%	8.55%	118.4%	-38.14%	58.89%	-28.39%	-27.47%	-36.25%	-36.64%	36.09%	-21.69%	908.87%	107.35%	-0.73%	28.04%	78.33%	-48.72%
Property, Plant & Equipment	$6.491M	$9.965M	$12.14M	$10.27M	$826.0K	$1.084M	$1.814M	$3.063M	$4.398M	$4.400M	$2.500M	$2.000M	$700.0K	$200.0K	$200.0K	$200.0K	$100.0K	$0.00	$0.00
YoY Change	-34.86%	-17.92%	18.2%	1143.46%	-23.8%	-40.24%	-40.78%	-30.35%	-0.05%	76.0%	25.0%	185.71%	250.0%	0.0%	0.0%	100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$1.757M	$1.758M	$2.080M	$1.871M	$2.317M	$2.321M	$1.997M	$1.966M	$2.300M				$0.00	$4.500M	$7.500M	$12.20M	$6.500M	$5.600M	$4.000M
YoY Change	-0.06%	-15.48%	11.17%	-19.25%	-0.17%	16.22%	1.58%	-14.52%					-100.0%	-40.0%	-38.52%	87.69%	16.07%	40.0%
Other Assets	$2.326M	$1.930M	$1.724M	$1.838M	$1.851M	$1.888M	$1.916M	$2.343M	$2.367M	$2.800M	$1.200M	$3.600M	$23.40M
YoY Change	20.52%	11.95%	-6.2%	-0.7%	-1.96%	-1.46%	-18.22%	-1.01%	-15.46%	133.33%	-66.67%	-84.62%
Total Long-Term Assets	$587.8M	$592.3M	$596.5M	$597.1M	$589.6M	$591.4M	$592.1M	$595.2M	$659.3M	$655.9M	$504.2M	$514.4M	$533.5M	$5.000M	$8.200M	$12.90M	$7.300M	$6.200M	$4.600M
YoY Change	-0.77%	-0.7%	-0.09%	1.27%	-0.3%	-0.12%	-0.52%	-9.72%	0.52%	30.09%	-1.98%	-3.58%	10570.0%	-39.02%	-36.43%	76.71%	17.74%	34.78%
Total Assets	$669.4M	$662.1M	$744.7M	$733.6M	$652.1M	$692.4M	$655.7M	$684.0M	$781.8M	$848.0M	$807.4M	$737.2M	$818.0M	$33.20M	$21.80M	$26.60M	$18.00M	$12.20M	$16.30M
YoY Change
Accounts Payable	$20.15M	$23.08M	$19.60M	$24.97M	$13.06M	$18.92M	$21.81M	$27.16M	$28.24M	$19.50M	$19.00M	$11.80M	$3.300M	$1.200M	$900.0K	$1.400M	$400.0K	$1.700M	$200.0K
YoY Change	-12.71%	17.76%	-21.52%	91.21%	-30.98%	-13.23%	-19.7%	-3.85%	44.83%	2.63%	61.02%	257.58%	175.0%	33.33%	-35.71%	250.0%	-76.47%	750.0%
Accrued Expenses	$2.013M	$3.333M	$4.195M	$5.748M	$4.231M	$4.358M	$3.811M	$2.019M		$4.600M	$500.0K	$400.0K	$700.0K	$100.0K	$0.00	$100.0K	$200.0K
YoY Change	-39.6%	-20.55%	-27.02%	35.85%	-2.91%	14.35%	88.76%			820.0%	25.0%	-42.86%	600.0%		-100.0%	-50.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$10.01M	$8.203M	$55.97M	$35.97M	$14.01M
YoY Change	22.05%	-85.34%	55.57%	156.83%
Total Short-Term Liabilities	$41.98M	$51.37M	$94.27M	$90.14M	$44.33M	$24.00M	$36.67M	$29.42M	$48.41M	$40.20M	$46.20M	$45.50M	$33.00M	$1.300M	$1.000M	$1.500M	$600.0K	$3.300M	$1.700M
YoY Change	-18.28%	-45.51%	4.58%	103.34%	84.69%	-34.54%	24.66%	-39.23%	20.42%	-12.99%	1.54%	37.88%	2438.46%	30.0%	-33.33%	150.0%	-81.82%	94.12%
Long-Term Debt	$106.5M	$98.70M	$49.53M	$63.34M	$67.28M	$59.40M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	7.88%	99.28%	-21.8%	-5.85%	13.27%
Other Long-Term Liabilities	$19.11M	$15.02M	$19.52M	$30.06M	$48.33M	$42.96M	$52.96M	$63.75M	$116.0M	$119.1M	$51.90M	$65.70M	$95.20M
YoY Change	27.22%	-23.03%	-35.08%	-37.8%	12.51%	-18.89%	-16.93%	-45.04%	-2.62%	129.48%	-21.0%	-30.99%
Total Long-Term Liabilities	$125.6M	$113.7M	$69.05M	$93.40M	$115.6M	$102.4M	$52.96M	$63.75M	$116.0M	$119.1M	$51.90M	$65.70M	$95.20M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	10.44%	64.71%	-26.08%	-19.21%	12.95%	93.28%	-16.93%	-45.04%	-2.62%	129.48%	-21.0%	-30.99%
Total Liabilities	$167.6M	$165.1M	$163.3M	$184.3M	$171.1M	$146.4M	$138.9M	$155.9M	$313.8M	$308.9M	$231.5M	$247.2M	$265.1M	$1.300M	$1.000M	$1.500M	$600.0K	$3.300M	$1.700M
YoY Change	1.5%	1.09%	-11.37%	7.72%	16.82%	5.41%	-10.87%	-50.33%	1.58%	33.43%	-6.35%	-6.75%	20292.31%	30.0%	-33.33%	150.0%	-81.82%	94.12%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005
Basic Shares Outstanding
Diluted Shares Outstanding
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Dividends

Stock Price

Market Cap: $1.0783 Billion

About

Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. The company is headquartered in Melbourne, Victoria and currently employs 83 full-time employees. The company went IPO on 2004-12-16. The company has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. The company is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. The company has established commercial partnerships in Europe and China for certain Phase III assets.

Industry: Biological Products, (No Diagnostic Substances) Peers: